In short
Clinical trials are investigating X-396 in people with ALK-positive non-small cell lung cancer. These studies aim to evaluate how well it works and how safe it is, especially compared with crizotinib. The main target group is patients who have had up to one prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor treatment.
Key points
- X-396 is being studied in clinical trials for ALK-positive non-small cell lung cancer. The main trial is a Phase 3 study comparing X-396 with crizotinib. It includes patients who have had up to one prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor treatment. The main outcome is progression-free survival, which shows how long the cancer does not get worse. The trial also looks at safety and uses independent radiology review with RECIST v. 1.1 to judge results.
Trial overview
The available trial is eXalt3, a study comparing X-396, also called ensartinib, with crizotinib in patients with ALK-positive non-small cell lung cancer (NSCLC). It is an interventional study, which means researchers give study treatments and then measure the results.
This trial is listed as Phase 3 and is authorised. The planned enrollment is 288 patients.
Who is being studied
The study is for people with ALK-positive NSCLC. The brief summary says patients may have had up to 1 prior chemotherapy regimen and must have had no prior ALK tyrosine kinase inhibitor treatment.
In simple terms, this means the trial is focused on patients whose lung cancer has a specific gene change and who have not yet been treated with this type of ALK-targeted medicine before.
What the trial measures
The main outcome is progression-free survival (PFS). This is the length of time before the cancer gets worse.
PFS is assessed by independent radiology review (IRR) using RECIST v. 1.1 rules. This means scan results are checked by independent experts using a standard method for measuring tumor changes.
Treatment comparison in the study
The trial compares X-396 capsules with crizotinib capsules. The intervention list includes X-396 capsules at 225 mg and XALKORI hard capsules at 200 mg or 250 mg.
Because this is a comparison study, the main goal is to see whether X-396 provides better results than the active comparator, crizotinib, in this patient group.
Trial design and phase
Phase 3 trials are larger studies that help show how well a treatment works and how safe it is in a defined patient group. In this trial, the focus is on both efficacy and safety of X-396 versus crizotinib in ALK-positive NSCLC.
The study design is important because it tests X-396 in a real treatment comparison, rather than only looking at the drug by itself. This helps researchers understand whether X-396 may be a useful option for patients who meet the study criteria.